be extended to other clinical situations.
D R U G D E L I V E R Y
The Fate and Toxicity of Raman-Active Silica-Gold Nanoparticles in Mice
INTRODUCTION
Noninvasive, molecular-based imaging allows the study of cellular and metabolic processes in living subjects in real time. This emerging field can contribute to many areas of biomedical research and clinical patient management, including patient screening by detection of disease-specific molecular markers, selection of disease-and patientspecific treatment, and measurement of molecular responses after treatment (1) (2) (3) . Current clinical molecular imaging approaches use positron emission tomography (PET) or single-photon emission computed tomography (SPECT). However, several new multimodality molecular imaging technologies are being explored. These include ultrasound (US) with molecularly targeted microbubble contrast agents, magnetic resonance spectroscopy (MRS), photoacoustic imaging, and optical imaging with either fluorescent molecular probes or Raman spectroscopy (4) . Nevertheless, no single molecular imaging modality meets all of the following criteria required for translation into everyday clinical practice: high sensitivity and specificity, high spatial and temporal resolution, multiplexing, safety, acceptability, and low cost.
Preclinical medical imaging of small animals with optical spectroscopy has traditionally relied on fluorescence. The potential for in vivo application of this method, however, has been limited by (i) the small number of fluorescent imaging agents available in the near-infrared spectrum, which limits the use of low-energy lasers to interrogate specimens; (ii) high background autofluorescence from superficial tissues, which restricts the sensitivity and depth of this imaging modality; (iii) the large spectral overlap between fluorescent imaging agents, which prevents the detection of multiple targets simultaneously (multiplexing); and (iv) the rapid photobleaching of fluorescent molecules, which limits study duration (5, 6) . Optical spectroscopy with the Raman effect shows great promise in overcoming many of these limitations.
The Raman effect describes how energy is exchanged between light and matter. When light impinges on a substance, it can be either absorbed or scattered. Because the energy of light is proportional to its frequency, most of the scattered light will have the same frequency as that of the incident light. However, a small fraction of the incident light can transfer some of its energy, thus shifting some molecules from their ground state into an excited vibrational state. This is accompanied by the simultaneous absorption of the incident photon and the emission of a Raman scattered photon. The energy exchange, and hence frequency shift, between the incident photon and Raman scattered photon is known as the Raman effect (7) . Raman spectroscopy is an invaluable bioanalytical tool that has the ability to differentiate the spectral fingerprint of many molecules, identifying the chemical composition of tissues with high sensitivity and minimal sample preparation (8) (9) (10) . Furthermore, as light can be rapidly delivered and collected by optical fibers, Raman spectroscopy has the potential to be performed in vivo, in real time, when incorporated into catheters and endoscopes (7) . However, the magnitude of the Raman effect is inherently weak (about 1 photon is inelastically scattered for every 10 7 elastically scattered photons), which limits the sensitivity and hence the clinical applications of Raman spectroscopy.
Advances in nanobiotechnology have enabled the synthesis of a Raman-silica-gold-nanoparticle (R-Si-Au-NP) that can overcome this problem by taking advantage of the phenomenon known as surfaceenhanced Raman scattering (SERS). SERS is a plasmonic effect in which molecules adsorbed onto a nano-roughened noble metal surface experience a marked increase in the incident electromagnetic field, thereby resulting in high Raman intensities (11) . The R-Si-Au-NPs consist of a Raman organic molecule, with a narrow-band spectral signature, adsorbed onto a 60-nm gold core (Fig. 1 ). This arrangement markedly increases the incident electromagnetic field of the Raman molecule layer via SERS, thereby markedly amplifying the intensity of the Raman signal. Because the Raman organic molecule can be changed, each nanoparticles can carry its own signature, thereby allowing multiple nanoparticles to be independently detected simultaneously in vivo in a process known as multiplexing (12) . The entire nanoparticle is encapsulated in a silica shell to hold the Raman organic molecule on the gold nanocore (Fig. 1) . The silica shell guarantees physical robustness, insensitivity to environmental conditions, and a surface with simple biofunctionalization properties. Polyethylene glycol (PEG)-ylation of R-Si-Au-NPs increases their bioavailability and provides functional "handles" for attaching targeting moieties. Currently, we are labeling our nanoparticle with an affibody, which will allow it to bind specifically to the epidermal growth factor receptor (EGFR). The physical (its relatively large size and spherical shape) and chemical (inert silica shell) characteristics of this nanoparticle have also been specifically optimized to minimize potential cellular toxicity (13) .
Nanoparticles have very different properties than do their corresponding bulk material; their small size will affect their mode of endocytosis, cellular trafficking, and processing. In addition, their high surface area/volume ratio, surface reactivity, and charge will markedly alter their chemical and physical properties, resulting in potential unexpected toxicities and biological interactions. Although several studies have been undertaken to investigate the toxicity associated with nanoparticles, the results are often highly variable, in part because of their different shapes, sizes, and chemical preparations (14) (15) (16) . Exposure of cultured human cells to PEG-R-Si-Au-NPs at low concentrations (1 to 100 PEG-R-Si-Au-NPs per cell) caused negligible toxicity. At very high concentrations, minimal cytotoxicity and oxidative stress were observed after prolonged exposure (1000 PEG-R-Si-Au-NPs per cell for 48 hours) (13) . Furthermore, the route of administration can also affect nanoparticle toxicity. Several studies have also shown that toxicity after intravenous (IV) administration of nanoparticles is limited by macrophages within the reticuloendothelial system (RES), in particular the liver, which efficiently remove low concentrations of nanoparticles from the systemic circulation (17, 18) . The PEG-R-SiAu-NPs that we are designing to target colon cancer are therefore not expected to cross the bowel wall when administered rectally, and if any do enter the systemic circulation, they would be directed to the liver by the portal venous system where they would be entrapped (17, 18) .
Here, we have tested this idea by examining in mice whether rectally (PR) administered PEG-R-Si-Au-NPs cause toxicity to the bowel and whether these nanoparticles cross the bowel wall. In case any nanoparticles do enter the circulation by crossing the bowel wall, we separately examined the systemic biodistribution and acute effects of directly administered PEG-R-Si-Au-NPs into the circulation via the IV route.
RESULTS

Nanoparticle concentration and administration volume
The concentration of PEG-R-Si-Au-NPs (9.6 × 10 10 nanoparticles in 200 ml of saline) administered to mice in both the IV and the PR experiments is a 1000 times higher dose than the minimum concentration that can be currently detected in vivo with a Raman microscope (6) . Provided that no toxic effects are observed in this study, this single/limit dose would be large enough to assess the effects of PEG-R-Si-Au-NPs. However, if significant toxic effects are observed, a graded dose-response analysis would be required. Furthermore, 200 ml of either saline (for control animals) or PEG-R-Si-Au-NPs was a small enough volume of fluid to have minimal impact on the animal's cardiovascular system.
General health indices
Male (n = 60) and female (n = 60) mice were followed daily for 2 weeks after either IV or PR PEG-R-Si-Au-NP administration. During this time, there were no deaths and no changes were observed in the physical appearance (fur, eyes, mucous membranes, secretions, stool, gait, posture, breathing pattern), behavior (gait, posture, stereotypes, vocalizations), or social interactions of all mice. In both male and female mice, no changes in the electrocardiogram (ECG) ( fig. S1 ), blood pressure, or heart rate (table S1) occurred after either IV or PR PEG-R-Si-Au-NP administration. The increase in body weight of all mice receiving PEG-R-Si-Au-NPs over 2 weeks was similar to that of control mice, with female mice being slightly lighter than their male counterparts at the start of the study (table S1). In both male and female mice, all plasma biochemical and hematological indices remained within their normal ranges after IV and PR PEG-R-Si-Au-NP administration (table S2) .
Gold levels
Because the nanoparticle core is made from gold, its biodistribution can be determined by measuring the concentration of gold within tissue samples by inductively coupled plasma mass spectrometry (ICP-MS). Gold was detected in the liver and spleen from male and female mice as early as 5 min after IV PEG-R-Si-Au-NP administration (Fig. 2) . Over the next 2 weeks, there was a gradual decline in the concentration of gold within the liver of male and female animals. In contrast, there was a significant increase in the concentration of gold in the spleen at 24 hours in both sexes compared to the 5-min and 2-hour time points, which gradually decreased over 2 weeks (Fig. 2) . Gold was detected in the blood of one of three female and two of three male animals 5 min after IV PEG-R-Si-Au-NP administration, but no gold was detected at later time points. Five minutes after PR PEG-R-SiAu-NP administration, we detected gold in the feces of both male and female mice but we found no gold at later time points. A trace concentration of gold was also detected in a blood sample of a single female mouse at 5 min after PR PEG-R-Si-Au-NP and in a lung sample of a single male mouse at 5 min after IV PEG-R-Si-Au-NP administration. Examination of the bone marrow, colon, small intestine, kidney, brain, gonads, and feces demonstrated no detectable gold after either IV or PR PEG-R-Si-Au-NP administration in all mice at any time. Over 2 weeks, the level of gold within the liver slowly declined after IV PEG-R-Si-Au-NP, as determined by ICP-MS, suggesting that some PEG-R-Si-Au-NPs are probably being removed from the animal via hepatobiliary excretion. However, because PEG-R-Au-NPs do not cross the bowel wall and are not absorbed by intestinal cells, the only way to confirm this would have been to collect, separate, and analyze all the feces and urine produced by all IV-injected mice over the 2 weeks. Although we did collect samples of feces and, when possible, urine for analysis by ICP-MS, this is only a snapshot representation of a dynamic excretory process, and hence, it is not surprising that no gold was detected in these samples. There was a peak in gold concentration within the spleen at 24 hours, suggesting that up to this time, PEG-R-Si-Au-NPs were still being redistributed within animals. In a single male animal, a small concentration of gold [1.31 parts per million (ppm)/g] was detected in a lung sample at 5 min. In this case, it is likely that some of the PEG-R-Si-Au-NPs in this animal bypassed the macrophages in the liver and spleen but were subsequently removed from the circulation by macrophages within the lung, which is another organ of the RES.
A mild degree of mitosis was also seen in male and female mice at 24 hours and 1 week after both IV saline and PEG-R-Si-Au-NP administration. This phenomenon has been previously observed and can be attributed to stretch-induced localized proliferation of hepatocytes due to swelling of liver sinusoids after a tail vein injection (19) . The stretching of cells increases DNA synthesis and cell proliferation by activating tyrosine kinases and protein kinase C (20) . In addition, the release of other growth factors and stimuli from the neighboring cells that have undergone apoptosis may also contribute to the local mitotic response (19) .
Tissue histology
After IV PEG-R-Si-Au-NP administration, detailed necropsy of the mouse by a mouse pathologist did not reveal any gross organ abnormality or evidence of nanoparticles in the spleen, bone marrow, pancreas, colon, small intestine, heart, kidneys, lungs, brain, and gonads in male or female animals. However, histological analysis of liver samples 5 min after IV PEG-R-Si-Au-NP administration revealed very fine black extracellular pigment within the perisinusoidal space in both male and female mice (Fig. 3, fig. S2 , and Table 1 ). After 2 hours, similar pigment was also seen intracellularly within resident macrophages of the liver. Because the amount of pigment within macrophages increased over 24 hours, less was observed in the sinusoids. By 2 weeks, pigment was only observed within the macrophages, with none present within the liver sinusoids (Fig. 3, fig. S2 , and Table 1 ). No animal demonstrated pigment within hepatocytes at any time point. Twentyfour hours after IV PEG-R-Si-Au-NP administration, a mild degree of hepatocellular apoptosis and necrosis was noted within the liver, which was no longer evident after 1 week. A slight increase in observable mitotic figures in hepatocytes was also seen in the livers of male and female mice at 24 hours and 1 week after both IV saline and PEG-R-Si-Au-NP administration.
After PR PEG-R-Si-Au-NP administration, there was no gross organ abnormality or evidence of nanoparticles in the spleen, pancreas, colon, small intestine, heart, kidneys, lungs, brain, and gonads in both male and female animals. Liver tissue from all animals revealed no pigment within the sinusoids, macrophages, or hepatocytes at all times examined after PR nanoparticle administration (Fig. 4, fig. S3 , and Table 1). Similar to the IV experiments, there was a mild degree of mitosis within the liver in both male and female mice 1 week after both PR saline and PEG-R-Si-Au-NP administration (Fig. 4, fig. S3 , and Table 1) . A large amount of very fine black pigment was noted within the colonic lumen of all animals at 5 min after PR PEG-R-Si-Au-NP administration, with no pigment subsequently seen within the bowel by 2 hours. Furthermore, no pigment was seen at any time point within the enterocytes of the bowel wall.
Scanning transmission electron microscopy
Scanning transmission electron microscopy (STEM) was performed to further evaluate the intracellular location of PEG-R-Si-Au-NPs. After IV PEG-R-Si-Au-NP administration, STEM analysis of liver samples demonstrated nanoparticles within the macrophages in all animals at each time point of interest. After 5 min, most PEG-R-Si-Au-NPs were seen within the perisinusoidal space with only a small number located within the vesicles of resident macrophages located adjacent to the sinusoids. By 2 hours, the number of nanoparticles internalized by resident macrophages had increased, and by 24 hours, STEM revealed large numbers of PEG-R-Si-Au-NPs within the vesicles of macrophages with no PEG-R-SiAu-NPs detected within the perisinusoidal space (Fig. 3, fig. S2 , and movie S1).
No PEG-R-Si-Au-NP could be identified with STEM within the liver sinusoids, macrophages, or hepatocytes at any time point examined after PR administration in both male and female mice.
Immunohistochemistry
Immuohistochemical analysis of liver and spleen samples was undertaken to verify the colocalization of PEG-R-Si-Au-NPs with macrophages. However, despite two separate attempts by independent laboratories, control and experimental tissues did not react with the monoclonal antibody against the F4/80 macrophage-specific antigen.
TUNEL assay
After IV PEG-R-Si-Au-NP administration, a representative female animal demonstrated 1 TUNEL-positive cell per 100 counted cells at 2 and 24 hours, whereas a representative male animal demonstrated 1 TUNEL-positive cell per 100 counted cells at 5 min and 2 TUNEL-positive cells per 100 counted cells at 2 weeks (table S3) . TUNEL-positive cells were identified as those with diffuse, brown, intranuclear staining. There were no TUNEL-positive cells in any of the representative liver samples after PR PEG-R-Si-Au-NP administration in either sex (table S3) . Furthermore, there were no TUNEL-positive cells identified in the splenic samples after either IV or PR PEG-R-Si-Au-NP administration in both male and female animals.
Gene expression
After IV PEG-R-Si-Au-NP administration, there was an increase in the gene expression of phase 2 antioxidant enzymes within the liver (Fig. 5 ). The mRNA levels of catalase and superoxide dismutase both peaked at 1 week, with the former demonstrating a gradual increase over the preceding time points (Fig. 5) . The peak increase in hemoxygenase occurs earlier at 24 hours, with the level of glutathione peroxidase maximal at 5 min (Fig. 5) . The Bax/Bcl-2 ratio, which controls activation of cellular apoptotic effectors, was also significantly increased at 5 min and 2 hours after IV PEG-R-SiAu-NP administration (Fig. 6 ). In contrast, the expression of tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), and caspase increases significantly later at 24 hours after IV PEG-R-Si-Au-NP administration (Fig. 6) . By 2 weeks, there was no significant increase in the mRNA of the antioxidant enzymes and proinflammatory or proapoptotic genes after IV PEG-R-Si-Au-NP administration compared to control animals (Figs. 5 and 6).
Toxicity of targeted PEG-R-Si-Au-NP Initial pilot studies with a prototype tumor-targeted nanoparticle construct have been undertaken in collaboration with the Nanocharacterization Lab (NCL) at the National Cancer Institute (NCI). Here, PEG-RSi-Au-NPs were conjugated with the heptapeptide sequence VRPMPLQ using simple amine chemistry. In five male and five female mice, 200 ml of 0.8 nM VRPMPLQ-PEG-R-Si-Au-NP (=9.6 × 10 10 tumor-targeted nanoparticles) was rectally administered. All mice were killed 3 days after PR VRPMPLQ-PEG-R-Si-Au-NP administration and gastrointestinal penetration analysis commenced. Necropsy included (i) ICP analysis of sentinel organs (liver and colon), feces, and urine; (ii) detailed histopathology of all major tissues; and (iii) hematology and clinical chemistry panels. The results show that in all experimental mice, no nanoparticles were detected in the systemic circulation 3 days after PR VRPMPLQ-PEG-R-Si-Au-NP administration. In addition, ICP analysis only revealed gold content within the feces, with undetectable amounts of gold in sentinel organs (liver and colon). Histopathology revealed healthy tissues in all mice with no biological effects of VRPMPLQ-PEG-R-Si-Au-NPs. Comprehensive hematology and clinical chemistry panels were all normal. Because no VRPMPLQ-PEG-R-Si-Au-NPs entered into blood, it is therefore unlikely that these nanoparticles cause any systemic toxicity. However, more detailed studies may be needed to study different types of targeted particles for any potential toxicity.
DISCUSSION
Our results show that IV or PR PEG-R-Si-Au-NP administration had no effect on the physical appearance, behavior, or social interactions in any of the mice studied. Regardless of the route of administration, PEG-R-Si-Au-NPs also had no acute effect on basal cardiovascular function or any of the hematological and biochemical parameters that we measured. The results show that the liver and spleen, which are organs of the RES, can effectively and efficiently remove PEG-R-Si-Au-NPs from the systemic circulation. Histological analysis of liver samples after IV PEG-R-Si-Au-NP administration supports the ICP-MS data and demonstrates uniform, very fine (<1 mm diameter), black, extracellular pigment within the perisinusoidal space (space of Disse) in both male and female mice. This pigment did not histochemically react with Prussian blue methods or the Fontana-Masson method, implying that the pigment was not ferrous-or melanin-based. Coupled with its uniformly fine diameter and its extracellular location, the pigment was therefore determined to represent the PEG-R-Si-Au-NPs. STEM of liver samples at early time points demonstrates the presence of PEG-R-Si-Au-NPs within the perisinusoidal space, with only a small number within the vesicles of resident macrophages located adjacent to the sinusoids. As time progressed, most PEG-R-Si-Au-NPs were internalized by resident macrophages with no PEG-R-Si-Au-NPs detected within the perisinusoidal space at the end of the study. Because PEG-RSi-Au-NPs were mainly located within the sinusoids at the early time points, and not trapped by cellular material, it is possible that there was some PEG-RSi-Au-NP loss during the sample preparation for STEM analysis at these times. Histologically, the spleens of all mice appeared normal, but specific assessment of the spleen for the presence and amount of PEG-R-Si-Au-NPs was inconclusive, primarily due to the presence of the ironcontaining hemosiderin pigment within splenic macrophages (hemosiderophages).
In all mice in this study, there was a moderate amount of splenic hemosiderophages, most likely representing normal physiologic extramedullary hematopoiesis in murine spleens. However, the amount and appearance of the hemosiderin (dense, golden brown, variably sized, coarse intracytoplasmic pigment granules) on hematoxylin and eosin (H&E) overwhelmed the very fine, black, granular appearance of the PEG-R-Si-Au-NPs on H&E sections. Prussian blue staining did not alleviate this problem, because the intense dark blue nature of the positive-staining hemosiderin also overwhelmed the fine, black, granular appearance of the PEG-R-Si-Au-NPs. In summary, PEG-R-Si-AuNPs are efficiently removed from the systemic circulation by the RES where they are taken up by resident macrophages. To reduce aggregation, the surface charge and coating of nanoparticles can be changed with the addition of PEG (21) . In addition, nanoparticles are likely to be opsonized by serum proteins (that is, clotting and complement proteins), which tag them for RES clearance. PEGylation increases nanoparticles' bioavailability by protecting them from opsonization and thereby reducing their interaction and uptake by macrophages (17) . However, our results show that PEG-R-Si-Au-NPs, with a 5:1 ratio of Mal-PEG 2000 -OME to Mal-PEG 5000 -NHS, are still efficiently taken up by the RES. This ratio would be ideal for PEG-R-Si-Au-NPs introduced into the bowel lumen, because any nanoparticles that manage to enter the systemic circulation will be rapidly removed by the RES, thereby limiting their potential for causing toxicity. Future clinical applications that require IV administration of PEG-R-Si-Au-NPs would need a different PEG ratio tailored to prolong bioavailability.
Despite there being no pigment within hepatocytes at any time after IV PEG-R-Si-Au-NP administration, a mild degree of hepatocyte apoptosis was seen in all animals 24 hours after injection with PEG-R-Si-Au-NPs. The peak in apoptosis coincided with the time when the most pigment, and thus PEG-R-Si-Au-NPs, was seen in macrophages. We therefore hypothesize, and offer indirect support, that macrophages can signal neighboring hepatocytes to undergo apoptosis. Because PEG-R-Si-Au-NPs are known to cause an increase in free radical formation (13), they may induce an increase in cellular oxidative stress within hepatocytes and macrophages. Our data support this possibility and show an increase in the gene expression of phase 2 antioxidant enzymes within the liver. Despite an early increase in glutathione peroxidase and hemoxygenase transcription, the initial antioxidant defenses were probably overwhelmed because hepatocytes still increased their Bax/Bcl-2 ratio, which is known to activate cellular proapoptotic mechanisms (22) . As a result, expression of inflammatory (TNF-a and IL-6) and apoptotic (caspase) genes was increased by 24 hours, which resulted in hepatocyte apoptosis, as seen histologically and circumstantially confirmed by TUNEL assay. However, no apoptosis was seen by 1 week after injection, which can be explained by an increase in gene expression of catalase and superoxide dismutase, both of which inhibit apoptosis by removing superoxide free radicals and hydrogen peroxide, respectively (23) . Together, these results suggest that the liver initiates a controlled apoptotic response to PEG-R-Si-Au-NPs in the acute phase after exposure. Given the regenerative capacity of the liver and its role as a filter within the RES, this acute-phase response seems necessary for the liver to eliminate foreign material that it extracts from the circulation in a controlled and regulated manner.
After PR administration, PEG-R-Si-Au-NPs were cleared from the bowel after 5 min with no nanoparticles detected systemically within any organ for the duration of the study. In a single female mouse, there was a trace concentration of gold within the blood at 5 min and 2 hours after exposure. This was probably due to a slightly traumatic colonic catheterization that could have resulted in a small breach in the integrity of the colonic epithelium, thereby allowing PEG-R-Si-Au-NPs to enter the circulation. Another possibility may have been increased absorption of nanoparticles by colonic macrophages within the gutassociated lymphoid tissue in this animal. The results therefore suggest that nontargeted PEG-R-Si-Au-NPs remain in the bowel lumen, do not cross the bowel wall, and are effectively eliminated from animals by defecation.
The detection of any single molecular biomarker will not provide clinicians with enough confidence to diagnose and characterize a disease process. Instead, multiple biomarkers will need to be detected to diagnose and detect diseases with high specificity and sensitivity, especially with complex diseases such as cancer that arise from many accumulated mutations. Hence, the ability to detect multiple targets, simultaneously, in vivo, has been the focus of many molecular imaging strategies, although not yet with nanoscale-based platforms (24) (25) (26) . Fluorescent nanoprobes, quantum dots, and R-Si-Au-NPs are the predominant molecular imaging probes being assessed for in vivo multiplex imaging. However, both fluorescent nanoprobes and quantum dots are limited by autofluorescence, susceptibility to photobleaching, and relatively broad emission spectra that limit their ability to colocalize multiple nanoprobes. Under certain conditions, quantum dots are cytotoxic, limiting their application in humans (27) . R-Si-Au-NPs do not suffer from these limitations and can be detected at picomolar concentrations, which is almost 1000 times lower than imaging with quantum dots (12) . In addition, five spectrally unique R-Si-Au-NPs can be identified and spectrally separated in vivo, thereby supporting their development for future translation into humans as a molecular imaging probe to be used with Raman spectroscopy. Although long-term studies are also still necessary to examine the fate of PEG-R-Si-AuNPs in the body, our encouraging results show that PEG-R-Si-AuNPs are not toxic in the short term and thus support the continued development of this nanoparticle as a molecular imaging probe. In particular, further work can now be undertaken to target these nanoparticles to molecular biomarkers up-regulated in specific diseases.
One of the limitations of any optical imaging technique, including Raman spectroscopy, is limited depth penetration. Hence, we are applying Raman spectroscopy with targeted PEG-R-Si-Au-NPs to detect diseases within hollow viscera, thereby allowing a Raman laser within the lumen to be in close proximity to the tissue being interrogated. A uniquely designed Raman endoscope could detect targeted PEG-R-Si-Au-NPs applied into the bowel lumen during routine colonoscopy to detect colon cancer. This could provide clinicians with a powerful biologically driven imaging technique and a specifically designed device to detect early colon cancer, including flat lesions (28) , in real time. The advantage of initially focusing on colon cancer is its high prevalence. In addition, any potential long-term effects of PEG-R-Si-Au-NPs will be minimized because nanoparticles would be excreted from the body after the procedure. Currently, we are identifying molecular biomarkers that are specifically up-regulated in human colon cancer. One example is the EGFR (29, 30) and another strategy relies on a heptapeptide sequence, VRPMPLQ, which binds to premalignant colon cancer tissue with high affinity (31) . We are in the process of optimizing the labeling of PEG-R-Si-Au-NPs either with an affibody that binds specifically to the EGFR or with the heptapeptide sequence VRPMPLQ. Once we have proven the ability of targeted PEG-R-Si-Au-NP to bind to human dysplastic colonic tissue with a high sensitivity and specificity, further toxicity studies will need to be undertaken to examine whether these functionalized nanoparticles are processed differently by living animals. This is especially important because recent studies have shown that functionalized or coupled nanoparticles are taken up by colon cancer cells significantly more readily than are uncoupled nanoparticles (32) . However, we have undertaken pilot studies with a prototype tumor-targeted nanoparticle construct (for example, VRPMPLQ-PEG-R-Si-Au-NP) in collaboration with the NCL at the NCI. The preliminary results show that in a small cohort of mice, peptide-functionalized PEG-R-Si-Au-NPs do not get into the blood after colorectal administration, supportive of a lack of systemic toxicity of these functionalized nanoparticles. Other potential applications for these nanoparticles include the detection of other cancers that can be reached endoscopically such as esophageal, stomach, small bowel, bronchial, and bladder cancer. Because therapeutic drugs can also be conjugated to PEG-R-Si-Au-NPs, the development of an integrated diagnostic and therapeutic nanoparticle is possible in the future.
MATERIALS AND METHODS
Animals
All animal experiments were conducted in compliance with the relevant guidelines and regulations approved by the Stanford Administrative Panel on Laboratory Animal Care (APLAC). A total of one hundred and twenty 5-week-old male and female FVB mice were obtained from a pathogen-free colony (Charles River Laboratories). Male and female FVB mice were chosen to assess the response to PEG-R-Si-Au-NPs because they have fully competent immune systems. Mice were housed in same-sex groups with three animals per cage. Water and food were available to all mice ad libitum. The environmental conditions were carefully monitored and maintained within an acceptable range throughout the study (temperature, 66 ± 2°F; relative humidity, 39 ± 1%; 12-hour light/dark cycle). All animals were quarantined for 7 days before the commencement of any experimental studies.
Nanoparticle characteristics
The R-Si-Au-NPs were obtained from Oxonica Materials Inc. and consisted of a 60-nm gold core, a Raman organic molecule, and a 30-nm silica shell, making the entire nanoparticle on the order of 120 nm in diameter (Fig. 1) . This arrangement markedly increases the incident electromagnetic field of the Raman-active organic molecule, thereby significantly amplifying its Raman signal intensity. Recent studies by our group have shown that these R-Si-Au-NPs have ultra-high sensitivity and can be detected at picomolar concentrations in vivo (6) . In addition, because the bound Raman organic molecule can be altered between different nanoparticles, different R-Si-Au-NPs are therefore able to provide different spectral signatures. Accordingly, we have shown the ability of Raman spectroscopy to separate the spectral signature of five different R-Si-Au-NPs in a living mouse after IV injection (12) . The particular lot used in this study was the S440 batch, which consists of a unique Raman material layer [trans-1,2-bis(4-pyridyl)-ethylene] and its associated spectrum that is detailed in previous work (6) . The R-Si-Au-NPs were PEGylated, but not further functionalized (for example, using targeting peptides), to study the core nanoparticle. Two different-sized PEG molecules, Mal-PEG 2000 -OME and Mal-PEG 5000 -NHS, were added to the surface of the R-Si-Au-NP in a 5:1 ratio, respectively. The smaller Mal-PEG 2000 -OME was added to improve nanoparticle biocompatibility, whereas the larger Mal-PEG 5000 -NHS was added to provide a functional group for potential ligand attachment. Both surface PEG chains were added to the surface of these nanoparticles in a two-step process. Initially, thiol groups were introduced into the silica shell of the nanoparticle using 3-mercaptopropyltrimethoxysilane. This was followed by conjugation with maleimide-activated methoxy PEGs (mPEGs), where the maleimide group reacted with the thiol group on the nanoparticle surface at neutral pH. To ensure consistency between the experiments, we created all PEG-R-Si-Au-NPs at the same time from the same batch of stock nanoparticles received from Oxonica Materials Inc. All nanoparticles were stored at 4°C between experiments.
Experimental protocol
To assess the effect of IV and PR R-Si-Au-NP administration, we randomly allocated mice into two experimental groups, each containing 60 mice with an equal male-to-female sex ratio ( fig. S4 ). In the IV group, three male and three female mice for each time point were given a 200-ml IV injection (via the tail vein) of either sterile saline or PEG-R-Si-Au-NPs. Because the concentration of the stock solution of nanoparticles provided by Oxonica Materials Inc. was 0.8 nM, using Avogadro's constant (6.022 × 10 23 elementary entities per mole of substance), we determined that there were 481,760,000 PEG-R-SiAu-NPs per microliter of stock solution. From this information, we were able to achieve a final concentration of 9.6 × 10 10 nanoparticles in 200 ml of saline. Mice in the PR group were fasted overnight in special metabolic cages with wire floors that allowed any feces produced to drop into a waste container. This prevented mice from having access to their feces during the fasting period, thereby ensuring that their large bowel was completely evacuated and prepared before any PEG-R-SiAu-NP administration. The following day, three male and three female mice for each time point were given a 200-ml PR injection of either sterile saline or PEG-R-Si-Au-NPs with a 24-gauge angiocatheter. All mice were euthanized by carbon dioxide asphyxiation at specific time points: 5 min, 2 hours, 24 hours, 1 week, and 2 weeks after PEG-R-SiAu-NP administration ( fig. S4 ).
Mice that were euthanized at 2 weeks after PEG-R-Si-Au-NP administration were carefully monitored throughout the study. For each mouse, their physical appearance (fur, eyes, mucous membranes, secretions, stool, gait, posture, breathing pattern), behavior (gait, posture, stereotypes, vocalizations), and interactions toward other animals were assessed and recorded daily. The body weight and cardiovascular status [ECG measurements using subcutaneous electrodes and blood pressure and heart rate measurements using a tail vein cuff device (Coda 6, Kent Scientific Corp.)] for each mouse were also recorded weekly. In addition, 200 ml of blood was collected from each mouse via retroorbital bleeding through a heparin-coated glass tube 1 week before PEG-R-Si-Au-NP administration to determine the baseline complete blood count (CBC), chemistry, and electrolyte panels (Veterinary Service Centre, Department of Comparative Medicine, Stanford University). Because APLAC protocol restricted subsequent blood withdrawal to <200 ml for each animal, only CBC and chemistry panels were determined at the beginning of the second week after PEG-R-Si-Au-NP administration. Blood samples for electrolytes were subsequently taken at the end of the second week immediately after euthanasia via cardiopuncture. However, it was not possible to analyze chemistry panels from samples collected via cardiopuncture due to the well-described phenomenon of muscle tissue contamination encountered with this particular blood collection procedure (33) . Before any blood sample collection, all mice were fasted overnight.
Pathologic evaluation
A complete postmortem examination was performed on each mouse at all time points, and each mouse was examined for gross changes. Samples of all major organs and tissues were collected and fixed in neutral-buffered 10% formalin for 48 hours. Fixed samples of liver, spleen, colon, small intestine, heart, kidneys, lungs, brain, and gonads were then routinely processed and stained with H&E (Histotec Laboratories) for light microscopy. Histopathological examination was performed by a veterinary pathologist blinded to other findings. Histopathologic diagnosis was performed according to the Standardized System of Nomenclature and Diagnostic Criteria (SSNDC).
Immunohistochemistry
To assess the colocalization of PEG-R-Si-Au-NPs and macrophages, we chose and immunostained paraffin-embedded, formalin-fixed liver and spleen tissues from a representative male and female administered with PEG-R-Si-Au-NP from each time point with a rat anti-mouse purified monoclonal antibody against the F4/80 macrophage-specific membrane antigen (AbD Serotec). Tissues were cut 4 mm thick by a microtome and stained with a Streptavidin-HRP (horseradish peroxidase) immunoperoxidase method. Endogenous peroxidase activity was inhibited by 3% hydrogen peroxide for 10 min followed by enzyme digestion in trypsin for 15 min at room temperature. Sections were then incubated for 2 hours with the primary F4/80 antibody. A saline-treated animal was used as a positive control, and an animal that had both received PEG-R-Si-Au-NPs and been incubated without the primary antibody was used as a negative control. After three washes with phosphate-buffered saline (PBS) for 5 min each, the sections were incubated for 30 min with a goat anti-rat biotinylated secondary antibody for 30 min. StreptAvidin-HRP was applied for 30 min and reacted with diaminobenzidine hydrochloride and counterstained with hematoxylin. Immunostained sections were then evaluated by a veterinary pathologist.
Despite two separate attempts by independent laboratories, control and experimental tissues did not react with the monoclonal antibody against the F4/80 macrophage-specific antigen. The failure of the F4/80 antibody to immunoreact with the macrophages in the tissues of our control and experimental mice could be due to significant alterations in the epitope structure of the F4/80 macrophage antigen (for example, inappropriate fixation or inherent differences in the F4/80 epitope in this group of mice), incorrect methodology (for example, failure to replicate the manufacturer's instructions), or issues with the antibody used itself (for example, incorrect generation of the appropriate antibody and incorrect storage/transport of the antibody). However, we feel that incorrect methodology is unlikely because the manufacturer's instructions were followed originally (with subsequent attempts to make the antibody "work" deviating from the manufacturer's instructions based on each laboratory's experience).
TUNEL assay
To assess the colocalization of PEG-R-Si-Au-NPs and apoptotic cells, we chose and stained paraffin-embedded, formalin-fixed liver and spleen tissues from a representative male and female animal from each time point, which had received PEG-R-Si-Au-NPs with an in situ terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) kit (Millipore), following the manufacturer's protocol for paraffin sections. Using a light microscope, a veterinary pathologist counted the number of positively stained cells per 100 cells.
Scanning transmission electron microscopy
During gross pathologic examination, samples of liver, spleen, colon, small intestine, kidneys, lungs, brain, and gonads (measuring~1 mm 3 ) were collected in a 2:1:1 solution of 0.2 M sodium cacodylate buffer/ 10% glutaraldehyde/8% paraformaldehye (EMSdiasum). Samples were then stored at 4°C before being stained en bloc with osmium tetroxide and uranyl acetate. Samples were then dehydrated in increasing concentrations of ethanol, followed by further dehydration with propylene oxide before being embedded in Embed 812 epoxy resin (EMSdiasum). Thin sections (150 nm) of each embedded tissue were cut with a Leica Ultracut S microtome and placed on 200-mesh bare copper grids. Sections were then examined with a Tecnai F20 (FEI) transmission electron microscope operating at 120 kV. STEM was used to analyze 12,500 mm 3 of tissue from each sample to determine the intracellular location of PEG-R-Si-Au-NPs. Tissue sections (150 nm) were also placed on a Formvar-coated 1 × 2-mm slot grid to collect a series of images at different tilt angles to perform a tilt series three-dimensional (3D) reconstruction. Dark-field STEM images were collected at one-degree intervals from −40°C to +25°C. Tilt series alignment and reconstruction were performed with assistance from FEI Company with the Inspect 3D reconstruction package.
Inductively coupled plasma mass spectrometry During gross pathologic examination, samples of liver, spleen, colon, small intestine, kidneys, lungs, brain, and gonads (measuring~1 mm 3 ) were collected to determine concentrations of gold in each of these tissues by ICP-MS analysis. Samples were prepared by microwaveassisted acid digestion to dissolve the gold core for ICP analysis using a mixture of trace metal grade 70% nitric acid (HNO 3 ; Fisher Scientific), 37% hydrochloric acid (HCl; Fisher Scientific), and 48% hydrofluoric acid (HF; Fisher Scientific). All samples were digested with HF to dissolve the outer silica shell of the PEG-R-Si-Au-NP, thereby freeing the elemental gold core for measurement by ICP-MS (34) . Samples were then air-dried, heated, and resuspended in freshly prepared aqua regia diluted with double-distilled water to 5× volume. ICP-MS was undertaken with a JA IRIS Advantage/1000 Radial ICAP Spectrometer, which was calibrated with a 2-ppm (Au) high standard and a 1-ppm (Au) QC standard [Gold ICP standard; 1 ml = 1 mg of Au (1000 ppm Au), Ricca Chemical, Fisher Scientific, PAU 1KH100] in dilute aqua regia matrix. On the basis of pilot experiments, the detection limit for the detection of gold was set at 0.019 ppm (Au). The reproducibility of the spectrometer was determined by measuring a series of different (Au) standards in triplicate: 1.0 ppm (Au) was measured to an accuracy of 0.9914 ± 0.0063, 0.1 ppm (Au) was measured to an accuracy of 0.1003 ± 0.0025, and 0.01 ppm (Au) was measured to an accuracy of 0.0103 ± 0.0010.
Assessment of antioxidant enzyme and inflammatory gene expression using qRT-PCR During gross pathologic examination, a sample of liver was collected and stored at −80°C. The change in gene expression in liver samples from animals that had been administered IV PEG-R-Si-Au-NPs was evaluated and compared with control animals that had received IV saline according to methods described previously (35) . Total RNA was extracted from sonicated liver tissue with RNeasy Plus Mini Kit (Qiagen), which contained genomic DNA (gDNA) eliminator spin columns to effectively remove gDNA. The RNA concentration in each sample was then calculated with the Qbit system (Invitrogen). Using 1 mg of RNA, we synthesized complementary DNA (cDNA) with reverse transcription (RT) by incubating samples at 25°C for 5 min followed by 42°C for 45 min with qScript cDNA Supermix (Quanta Biosciences), which contained buffer, deoxynucleotide triphosphates (dNTPs), MgCl 2 , random primers, ribonuclease (RNase) inhibitor, and reverse transcriptase. Quantitative RT-polymerase chain reaction (qRT-PCR) was then undertaken with the Realplex Mastercycler machine (Eppendorf) with PerfeCTa SYBR Green FastMix, which contained AccuFast Taq DNA polymerase (Quanta Biosciences). All samples were run in triplicate in a 20-ml reaction volume with cDNA of 100 ng of RNA equivalent, with an initial preheating phase of 95°C for 2 min followed by 60 cycles consisting of 95°C for 30 s, 55°C for 30 s, and 68°C for 30 s. Melting curve analysis was performed for each reaction to exclude nonspecific PCR side products. The primer sequences for antioxidant enzyme genes (catalase, superoxide dismutase, hemoxygenase, and glutathione peroxidase) and inflammatory genes (Bax, Bcl-2, caspase-3, IL-6, and TNF-a) along with the internal control (b-actin) are shown in table S4. Because the RNA extraction for some liver samples did not generate sufficient quantities of RNA to run qRT-PCR, male and female samples for the PEG-R-Si-Au-NP and control groups were analyzed together at each time point. Statistical analysis with a two-way repeated-measures analysis of variance (ANOVA) was therefore performed comparing the effect of time (5 min, 2 hours, 24 hours, 1 week, and 2 weeks) and treatment (IV or PR saline versus PEG-R-Si-Au-NP).
Statistical analysis
All quantitative variables are expressed as mean ± SEM. When possible, a three-way repeated-measures ANOVA was performed comparing the effect of time (5 min, 2 hours, 24 hours, 1 week, and 2 weeks), treatment (IV or PR saline versus PEG-R-Si-Au-NP), and sex (male versus female). Where a significant effect of time, group, or sex was indicated, the post hoc Student-Newman-Keuls test was used to isolate the statistical differences. For all comparisons, statistical significance was accepted when P < 0.05.
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